title: Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans.
abstract: Anthrax Vaccine Adsorbed (AVA, BioThrax) is approved for use in humans as a priming series of 3 intramuscular (i.m.) injections (0, 1, 6 months; 3-IM) with boosters at 12 and 18 months, and annually thereafter for those at continued risk of infection. A reduction in AVA booster frequency would lessen the burden of vaccination, reduce the cumulative frequency of vaccine associated adverse events and potentially expand vaccine coverage by requiring fewer doses per schedule. Because human inhalation anthrax studies are neither feasible nor ethical, AVA efficacy estimates are determined using cross-species bridging of immune correlates of protection (COP) identified in animal models. We have previously reported that the AVA 3-IM priming series provided high levels of protection in non-human primates (NHP) against inhalation anthrax for up to 4 years after the first vaccination. Penalized logistic regressions of those NHP immunological data identified that anti-protective antigen (anti-PA) IgG concentration measured just prior to infectious challenge was the most accurate single COP. In the present analysis, cross-species logistic regression models of this COP were used to predict probability of survival during a 43 month study in humans receiving the current 3-dose priming and 4 boosters (12, 18, 30 and 42 months; 7-IM) and reduced schedules with boosters at months 18 and 42 only (5-IM), or at month 42 only (4-IM). All models predicted high survival probabilities for the reduced schedules from 7 to 43 months. The predicted survival probabilities for the reduced schedules were 86.8% (4-IM) and 95.8% (5-IM) at month 42 when antibody levels were lowest. The data indicated that 4-IM and 5-IM are both viable alternatives to the current AVA pre-exposure prophylaxis schedule.
authors.affiliation: Centers for Disease Control and Prevention (CDC), Atlanta, GA 30333, United States. Electronic address: jschiffer@cdc.gov.
authors.forename: Jarad M
authors.initials: JM
authors.lastname: Schiffer
authors.affiliation: Atlanta Research and Education Foundation (AREF), Decatur, GA 30033, United States.
authors.forename: Ligong
authors.initials: L
authors.lastname: Chen
authors.affiliation: Atlanta Research and Education Foundation (AREF), Decatur, GA 30033, United States.
authors.forename: Shannon
authors.initials: S
authors.lastname: Dalton
authors.affiliation: Battelle, 505 King Avenue, Columbus, OH 43210, United States.
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Niemuth
authors.affiliation: Battelle, 505 King Avenue, Columbus, OH 43210, United States.
authors.forename: Carol L
authors.initials: CL
authors.lastname: Sabourin
authors.affiliation: Centers for Disease Control and Prevention (CDC), Atlanta, GA 30333, United States.
authors.forename: Conrad P
authors.initials: CP
authors.lastname: Quinn
mesh_terms: D000818:Animals; D000881:Anthrax / Q000276:immunology* / Q000517:prevention & control*; D022122:Anthrax Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000276:immunology; D001427:Bacterial Toxins / Q000276:immunology; D015415:Biomarkers / Q000032:analysis*; D056808:Biostatistics; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods*; D007074:Immunoglobulin G / Q000097:blood; D007273:Injections, Intramuscular; D023421:Models, Animal; D011323:Primates; D016019:Survival Analysis
chemical_list: D022122:Anthrax Vaccines; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D015415:Biomarkers; C493276:Biothrax; D007074:Immunoglobulin G; C030325:anthrax toxin
keywords: AVA; Animal model; Anthrax; Anthrax Vaccine Adsorbed; Bacillus anthracis; Biothrax; Clinical trial; Correlates of protection; Non-clinical trial